33 research outputs found
Galectin-3 Targeted Therapy with a Small Molecule Inhibitor Activates Apoptosis and Enhances Both Chemosensitivity and Radiosensitivity in Papillary Thyroid Cancer
Caracterizacao imunohistoquimica dos linfomas histiocitos verdadeiros pela pesquisa de antigenos do sistema histiocitico-macrofagico
BV UNIFESP: Teses e dissertaçõe
Adenomas hipofisários: determinantes biológicos de agressividade
BV UNIFESP: Teses e dissertaçõe
p53 in epidermoid cancer of the esophagus
BACKGROUND/AIMS: Wild type p53 protein has an inhibitory effect on cell proliferation and transformation. Mutation or deletion of the p53 gene can be the first point of malignancy, Abnormalities of the p53 protein gene have been linked with tumors of the esophagus.METHODOLOGY: In this study, we investigated the expression of the p53 gene in epidermoid carcinoma of the esophagus as well as in the basal layer near the tumor. We studied the expression of p53 in 24 esophageal tumors and in normal esophageal tissue near the tumor in 16 cases, using an immunohistochemical reaction.RESULTS: p53 Was positive in 18 esophageal tumors (75%) and in 15 of the 16 (94%) normal samples of esophageal tissue. There was no correlation between expression of the p53 gene and age, sex, tobacco intake, alcoholism, and familiar history of cancer or clinical stage of the disease. The mean survival of the p53 patients (negative or positive) was similar.CONCLUSIONS: p53 Accumulation was found in most cases of esophageal cancer as well as in samples of normal tissue close to the tumor. The positivity of p53 seems to be independent of clinical or pathological parameters and was not of any use in predicting prognosis in our study.UNIFESP EPM, Div Gastroenterol, Discipline Gastroenterol, BR-04023000 Sao Paulo, BrazilUNIFESP EPM, Dept Pathol, BR-04023000 Sao Paulo, BrazilUNIFESP EPM, Div Gastroenterol, Discipline Gastroenterol, BR-04023000 Sao Paulo, BrazilUNIFESP EPM, Dept Pathol, BR-04023000 Sao Paulo, BrazilWeb of Scienc
Recommended from our members
Membranous obliterative bronchitis : A proposed unifying model
Postoperative hungry bone syndrome in patients with secondary hyperparathyroidism of renal origin
Hungry bone syndrome (HBS) is a postoperative condition of severe hypocalcemia that can be seen in patients who have undergone parathyroidectomy (PTX) for secondary hyperparathyroidism (2HPT) of renal origin. This study examines HBS in patients after PTX for 2HPT.
Prospectively collected data was retrospectively reviewed in patients who underwent PTX for 2HPT of renal origin at a single institution. HBS was defined as the need for additional days of hospitalization or readmission for intravenous calcium supplementation due to clinical symptoms of hypocalcemia, including tingling, muscle spasms, and bone pain and/or immediate postoperative low serum calcium ≤7.5 mg/dl.
Of 79 patients who underwent PTX for 2HPT, 27.8% (n = 22) experienced HBS. Young age (≤45 years, p = 0.02) was the only preoperative variable that predicted HBS. Most patients developed HBS within 18 h after surgery and required a prolonged hospital stay (19/22) compared to those requiring hospital readmission within the first 7 days (3/22). Initial postoperative serum calcium levels within 18 h of surgery were significantly lower in those patients who developed HBS (7.1 vs. 8.3 mg/dl, p = 0.001), and those patients also had a greater absolute decrease in serum calcium (2.8 vs. 3.5 mg/dl, p = 0.04).
HBS develops in a significant proportion of patients generally within the first 18 h after subtotal PTX for 2HPT. The only identifiable preoperative risk factor for HBS was young age. Additionally, low initial calcium levels and greater absolute decrease in serum calcium may help identify those patients that will develop HBS requiring judicious calcium supplementation